-
Je něco špatně v tomto záznamu ?
Amphiphilic transdermal permeation enhancers: structure-activity relationships
Vávrová K, Zbytovská J, Hrabálek A.
Jazyk angličtina Země Nizozemsko
NLK
ProQuest Central
od 2000-01-01 do 2008-12-31
Health & Medicine (ProQuest)
od 2000-01-01 do 2008-12-31
PubMed
16178785
DOI
10.2174/0929867054864822
Knihovny.cz E-zdroje
- MeSH
- absorpce účinky záření MeSH
- aplikace kožní MeSH
- ceramidy aplikace a dávkování chemie MeSH
- farmaceutická chemie MeSH
- financování organizované MeSH
- hydrofobní a hydrofilní interakce MeSH
- keratiny metabolismus MeSH
- kůže metabolismus účinky léků MeSH
- lékové transportní systémy MeSH
- lipidy chemie MeSH
- permeabilita účinky léků MeSH
- rozpouštědla chemie MeSH
- vodíková vazba MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
Transdermal drug delivery offers numerous advantages over conventional routes of administration; however, poor permeation of most drugs across the skin barrier constitutes a serious limitation of this methodology. One of the approaches used to enlarge the number of transdermally-applicable drugs uses permeation enhancers. These compounds promote drug permeation through the skin by a reversible decrease of the barrier resistance. Enhancers can act on the stratum corneum intracellular keratin, influence desmosomes, modify the intercellular lipid domains or alter the solvent nature of the stratum corneum. Even though, hundreds of substances have been identified as permeation enhancers to date, yet our understanding of the structure-activity relationships is limited. In general, enhancers can be divided into two large groups: small polar solvents, e.g. ethanol, propylene glycol, dimethylsulfoxide and amphiphilic compounds containing a polar head and a hydrophobic chain, e.g. fatty acids and alcohols, 1-dodecylazepan-2-one (Azone), 2-nonyl-1,3-dioxolane (SEPA 009), and dodecyl-2-dimethylaminopropanoate (DDAIP). In this review we have focused on structure-activity relationships of amphiphilic permeation enhancers, including the properties of the hydrophobic chains, e.g. length, unsaturation, and branching, as well as the polar heads characteristics, e.g. hydrogen bonding ability, lipophilicity, and size. We present over 180 examples of enhancers with different polar head to illustrate the structural requirements and the possible role of the polar head. We have given an overview of the methods used for investigation of the mechanisms of permeation enhancement, namely differential scanning calorimetry (DSC), infrared (IR) and Raman spectroscopy, X-ray diffraction and future perspectives in this field. Furthermore, biodegradability and chirality of the enhancers are discussed.
Citace poskytuje Crossref.org
- 000
- 04016naa 2200481 a 4500
- 001
- bmc07506864
- 003
- CZ-PrNML
- 005
- 20111210122731.0
- 008
- 080908s2005 ne e eng||
- 009
- AR
- 024 __
- $a 10.2174/0929867054864822 $2 doi
- 035 __
- $a (PubMed)16178785
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vávrová, Kateřina $7 xx0118201
- 245 10
- $a Amphiphilic transdermal permeation enhancers: structure-activity relationships / $c Vávrová K, Zbytovská J, Hrabálek A.
- 314 __
- $a Department of Inorganic and Organic Chemistry, Charles University, Faculty of Pharmacy, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. katerina.vavrova@faf.cuni.cz
- 520 9_
- $a Transdermal drug delivery offers numerous advantages over conventional routes of administration; however, poor permeation of most drugs across the skin barrier constitutes a serious limitation of this methodology. One of the approaches used to enlarge the number of transdermally-applicable drugs uses permeation enhancers. These compounds promote drug permeation through the skin by a reversible decrease of the barrier resistance. Enhancers can act on the stratum corneum intracellular keratin, influence desmosomes, modify the intercellular lipid domains or alter the solvent nature of the stratum corneum. Even though, hundreds of substances have been identified as permeation enhancers to date, yet our understanding of the structure-activity relationships is limited. In general, enhancers can be divided into two large groups: small polar solvents, e.g. ethanol, propylene glycol, dimethylsulfoxide and amphiphilic compounds containing a polar head and a hydrophobic chain, e.g. fatty acids and alcohols, 1-dodecylazepan-2-one (Azone), 2-nonyl-1,3-dioxolane (SEPA 009), and dodecyl-2-dimethylaminopropanoate (DDAIP). In this review we have focused on structure-activity relationships of amphiphilic permeation enhancers, including the properties of the hydrophobic chains, e.g. length, unsaturation, and branching, as well as the polar heads characteristics, e.g. hydrogen bonding ability, lipophilicity, and size. We present over 180 examples of enhancers with different polar head to illustrate the structural requirements and the possible role of the polar head. We have given an overview of the methods used for investigation of the mechanisms of permeation enhancement, namely differential scanning calorimetry (DSC), infrared (IR) and Raman spectroscopy, X-ray diffraction and future perspectives in this field. Furthermore, biodegradability and chirality of the enhancers are discussed.
- 650 _2
- $a absorpce $x účinky záření $7 D000042
- 650 _2
- $a ceramidy $x aplikace a dávkování $x chemie $7 D002518
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a permeabilita $x účinky léků $7 D010539
- 650 _2
- $a kůže $x metabolismus $x účinky léků $7 D012867
- 650 _2
- $a aplikace kožní $7 D000279
- 650 _2
- $a farmaceutická chemie $7 D002626
- 650 _2
- $a vodíková vazba $7 D006860
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a keratiny $x metabolismus $7 D007633
- 650 _2
- $a lipidy $x chemie $7 D008055
- 650 _2
- $a rozpouštědla $x chemie $7 D012997
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Zbytovská, Jarmila. $7 xx0306236
- 700 1_
- $a Hrabálek, Alexandr, $d 1956- $7 nlk19990073261
- 773 0_
- $w MED00001274 $t Current medicinal chemistry $g Roč. 12, č. 19 (2005), s. 2273-2291 $x 0929-8673
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20080721085927 $b ABA008
- 991 __
- $a 20081009105840 $b ABA008
- 999 __
- $a ok $b bmc $g 622472 $s 474905
- BAS __
- $a 3
- BMC __
- $a 2005 $b 12 $c 19 $d 2273-2291 $i 0929-8673 $m Current medicinal chemistry $x MED00001274
- LZP __
- $a 2008-Doreen